Palbocent 125 MG (Palbociclib)
Product Name : Palbocent
Generic Name : Palbociclib
Formulation : Capsule
Available Pack Size : 3’s
Available Strengths : 125 mg
Registrations : Export Only
Product Information
Palbocent (Palbociclib) 125mg is a selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor used in combination with endocrine therapy to treat hormone receptor-positive (HR-positive) advanced or metastatic breast cancer in adult patients. It works by blocking CDK4 and CDK6, proteins that cancer cells rely on to progress through the cell cycle and divide, thereby slowing or stopping tumour growth. Global supplier: Mediaid Pharmacy with worldwide shipping.
Basic Product Information of Palbocent (Palbociclib) 125mg
| Brand Name | Palbocent (Palbociclib) |
| Generic Name | Palbociclib INN |
| Drug Class | Cyclin-Dependent Kinase 4/6 (CDK4/6) Inhibitor |
| Available Strengths | 125mg |
| Formulation | Capsule |
| Pack Size | 3 Capsules per Pack. Each treatment cycle requires 21 capsules (one per day for 21 days, followed by a 7-day break), so continuous therapy requires multiple packs. |
| Primary Indication | HR-Positive Advanced or Metastatic Breast Cancer, in combination with endocrine therapy |
| Regulatory Approvals | USFDA Approved (HR+/HER2- with an aromatase inhibitor or fulvestrant; HR+/HER2- PIK3CA-mutated with inavolisib and fulvestrant; HR+/HER2+ maintenance with trastuzumab). EMA Approved (HR+/HER2- with an aromatase inhibitor or fulvestrant). |
| Originator Brand | Ibrance by Pfizer |
| Manufacturer | [Manufacturer name to be confirmed], Bangladesh |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Registration | Export Only |
| Storage Conditions | Store below 30 degrees Celsius. Keep in a dry place away from light and moisture. Keep out of the reach of children. |
How Palbocent (Palbociclib) Works
Palbocent contains Palbociclib, a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). CDK4 and CDK6 are enzymes that drive cells through the G1 to S phase transition of the cell cycle, a step that hormone receptor-positive breast cancer cells depend on heavily to keep dividing in response to oestrogen signalling.
Palbociclib works by blocking CDK4/6 activity, preventing phosphorylation of the retinoblastoma (Rb) protein and halting cell cycle progression. This stops cancer cells from dividing further, slowing or stopping tumour growth. Because hormone receptor-positive breast cancer cells are particularly reliant on this pathway, Palbocent is used alongside endocrine-based therapies that target the hormonal signals driving the cancer, giving a combined, complementary mechanism of action.
Palbocent is not chemotherapy; it is a targeted, once-daily oral capsule taken in a 21-days-on, 7-days-off cycle, allowing time for normal blood cell counts to recover between treatment periods.
Indications for Palbocent (Palbociclib)
Palbocent (Palbociclib) is indicated for the following conditions, always in combination with endocrine-based therapy:
|
With an Aromatase Inhibitor (First-Line) For adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor as initial endocrine-based therapy. |
With Fulvestrant (After Progression) For adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with fulvestrant in patients with disease progression following prior endocrine therapy. |
|
With Inavolisib and Fulvestrant For adult patients with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer, as detected by an approved test, following recurrence on or after adjuvant endocrine therapy. |
With Trastuzumab (HER2+ Maintenance) For adult patients with HR-positive, HER2-positive advanced or metastatic breast cancer, in combination with trastuzumab, with or without pertuzumab, and endocrine therapy, as maintenance following induction treatment. |
Benefits of Palbocent (Palbociclib) 125mg
|
First-in-Class CDK4/6 Inhibitor Palbocent was among the first CDK4/6 inhibitors approved for HR-positive breast cancer, with an extensive body of clinical evidence supporting its use. |
Broad Combination Versatility Approved with aromatase inhibitors, fulvestrant, inavolisib plus fulvestrant, and trastuzumab-based regimens, giving physicians flexibility across multiple breast cancer treatment settings. |
Targeted, Non-Chemotherapy Option Palbocent works through a targeted cell-cycle mechanism rather than broad cytotoxic chemotherapy, taken conveniently as an oral capsule at home. |
|
Affordable Alternative to Ibrance Palbocent contains the same active ingredient as Ibrance by Pfizer, at a significantly lower cost, improving access to CDK4/6-targeted breast cancer therapy. |
Structured Treatment Cycle The 21-days-on, 7-days-off dosing schedule allows planned recovery time for blood counts between active treatment periods. |
WHO-GMP and cGMP Certified Manufactured under strict WHO-GMP, cGMP, and ISO-certified standards, ensuring every batch of Palbocent meets consistent quality, safety, and efficacy requirements. |
How to Take Palbocent (Palbociclib)
Route: Oral, taken by mouth
Standard dose: 125mg (one capsule) once daily for 21 consecutive days, followed by 7 days off treatment, to complete a 28-day cycle. Continued in combination with the prescribed endocrine therapy or trastuzumab-based regimen until disease progression or unacceptable toxicity.
With food: Palbocent capsules must be taken with food, at about the same time each day, to ensure consistent absorption.
Missed or vomited dose: If a dose is missed or vomited, do not take an additional dose that day; resume the usual dosing schedule the next day.
Grapefruit: Avoid grapefruit, grapefruit juice, and Seville oranges during treatment, as these can increase Palbociclib levels.
Dose reductions for toxicity: Based on individual safety and tolerability, particularly neutropenia, the dose may be reduced in steps from 125mg to 100mg, and if needed to 75mg once daily on the same 21/7 schedule. If further reduction is required, treatment is discontinued.
Strong CYP3A inhibitor co-administration: Avoid where possible; if unavoidable, reduce the Palbocent dose to 75mg once daily for the duration of co-administration.
Swallowing: Swallow capsules whole. Do not take capsules that are broken, cracked, or otherwise damaged.
Monitoring and Dosage Adjustments
Regular monitoring is essential during Palbocent treatment. Your healthcare provider will monitor complete blood counts for neutropenia, leukopenia, anaemia, and thrombocytopenia, particularly at the start of each cycle and on Day 15 of the first two cycles. Monitoring also includes liver function and renal function, and watchfulness for pulmonary symptoms that could indicate interstitial lung disease or pneumonitis. Report any fever, signs of infection, new or worsening shortness of breath, or cough to your doctor immediately.
Drug Interactions and Important Information
Palbociclib is metabolised primarily by CYP3A. Avoid concomitant use of strong CYP3A inhibitors such as ketoconazole, clarithromycin, itraconazole, and ritonavir, and consider alternatives with minimal CYP3A inhibition; if unavoidable, reduce the Palbocent dose to 75mg once daily. Avoid strong CYP3A inducers such as rifampin, carbamazepine, phenytoin, and St. John’s Wort, as these can reduce Palbociclib efficacy.
Male patients with female partners of reproductive potential should use effective contraception during treatment and for 3 months after the final dose. Women should not breastfeed during treatment and for 3 weeks after the final dose. Always inform your physician of all medications, supplements, and herbal products you are currently taking before starting Palbocent.
Side Effects and Precautions
|
Common Side Effects Decreased blood cell counts (neutropenia, leukopenia, anaemia) Infections Diarrhoea and nausea Sore mouth (stomatitis) Fatigue Elevated liver enzymes and creatinine Headache and rash Hair thinning and electrolyte abnormalities |
Serious Warnings and Precautions Neutropenia, which may lead to serious or fatal infections, including febrile neutropenia. Interstitial lung disease / pneumonitis, which can be severe or fatal. Embryo-fetal toxicity. Not recommended during pregnancy. Male fertility impairment has been reported. Do not breastfeed during treatment and for 3 weeks after the final dose. Regular complete blood count monitoring is required throughout treatment. |
Who Should Use Palbocent (Palbociclib)?
Palbocent is suitable for adult patients diagnosed with hormone receptor-positive advanced or metastatic breast cancer, whether HER2-negative (used with an aromatase inhibitor, fulvestrant, or inavolisib plus fulvestrant) or HER2-positive (used as maintenance with trastuzumab-based therapy). It is prescribed by oncologists and specialist physicians experienced in managing breast cancer. Baseline and periodic blood counts, liver function, and pregnancy status (where relevant) should be assessed before and during treatment.
Manufacturer
Palbocent (Palbociclib) is manufactured in Bangladesh under strict WHO-GMP, cGMP, and ISO-certified standards for export markets, offering an affordable and bioequivalent alternative to Ibrance by Pfizer at a fraction of the cost. [Please confirm the exact manufacturer name so it can be added here and in the specs table above.]
Global Supplier: Mediaid Pharmacy with Worldwide Shipping
Mediaid Pharmacy is a trusted global supplier of specialty oncology medications. We ensure Palbocent (Palbociclib) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.
Why Choose Palbocent (Palbociclib) from Mediaid Pharmacy?
Palbocent represents an important treatment option for patients with hormone receptor-positive breast cancer. As the generic equivalent of Ibrance by Pfizer, it delivers the same active ingredient, Palbociclib, with the same proven CDK4/6 inhibition mechanism at a dramatically more affordable price. Manufactured under WHO-GMP and cGMP standards and distributed globally by Mediaid Pharmacy, Palbocent gives patients worldwide access to high-quality targeted breast cancer therapy without the financial burden of brand-name alternatives. For patients and physicians seeking a proven, affordable, and accessible Palbociclib option with worldwide delivery, Palbocent from Mediaid Pharmacy is the trusted choice.
Frequently Asked Questions About Palbocent (Palbociclib)
What is Palbocent (Palbociclib) used for?
Palbocent (Palbociclib) is a CDK4/6 inhibitor used in combination with endocrine therapy to treat hormone receptor-positive advanced or metastatic breast cancer in adults, including in combination with an aromatase inhibitor, fulvestrant, inavolisib plus fulvestrant, or trastuzumab-based regimens, depending on the specific tumour profile and treatment setting.
How should I take Palbocent (Palbociclib)?
Palbocent capsules are taken orally once daily with food, for 21 consecutive days followed by 7 days off treatment, making up a 28-day cycle. It is always used together with the endocrine or trastuzumab-based therapy prescribed by your physician. Always follow your prescribing physician’s exact instructions and do not stop or change your dose without medical advice.
What strength and pack size is Palbocent (Palbociclib) available in?
Palbocent is available as a 125mg capsule, supplied in packs of 3 capsules. Since each 28-day treatment cycle requires 21 capsules (one per day for the first 21 days), patients should plan to order enough packs to complete a full cycle without interruption.
Is Palbocent the same as Ibrance (Palbociclib by Pfizer)?
Yes. Palbocent is the generic equivalent of Ibrance. Both contain the same active ingredient, Palbociclib, in the same dosage form and strength. Palbocent delivers the same clinical benefits as Ibrance at a significantly lower cost, making it a more accessible option for patients worldwide.
What are the side effects of Palbocent (Palbociclib)?
The most common side effect is a drop in blood cell counts, particularly neutropenia, along with infections, diarrhoea, sore mouth, nausea, and fatigue. Serious but less common risks include severe neutropenia with infection, interstitial lung disease, and embryo-fetal toxicity. Regular blood count monitoring is required throughout treatment. Always consult your physician for a complete assessment of your individual risks and benefits.
Can Palbocent be used with other medications?
Palbocent is always prescribed together with an endocrine therapy (such as an aromatase inhibitor or fulvestrant) or a trastuzumab-based regimen, as directed by your oncologist. Strong CYP3A inhibitors and inducers can significantly affect Palbociclib levels, so all concomitant medications should be reviewed with your prescribing physician.
Is Palbocent (Palbociclib) safe during pregnancy or breastfeeding?
No. Palbocent is not recommended during pregnancy or breastfeeding due to the risk of embryo-fetal toxicity. Effective contraception is required during treatment and for a period after the final dose, for both female patients and male patients with partners of reproductive potential. Please consult your physician before starting treatment if you are pregnant, planning to become pregnant, or breastfeeding.
Can I order Palbocent (Palbociclib) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Palbocent (Palbociclib) 125mg globally with worldwide shipping. Contact us via WhatsApp, phone, or WeChat at +8801773428128 or email us at info@mediaidpharmacy.com to enquire about pricing, availability, and delivery to your country.
Order Palbocent (Palbociclib) 125mg with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com
